PANTHERARecruiting

Pelvic Floor Function in Cancer Patients During Tumor Therapy

Gender
Women and men
Age
18 years and older
Trial type
Observational
Line of therapy
all
Phase
—

What is this trial about?

The treatment of gynecological tumors and breast cancer—especially in advanced stages—often requires intensive cancer therapy, which can lead to pelvic floor weakness. The goal of the PANTHERA study is to assess and analyze the subjective limitations in bladder, bowel, and sexual function, as well as their impact on patients’ quality of life. Women and men who are currently receiving drug therapy for breast cancer or gynecological tumors are eligible to participate in the study.

Trial flow

Requirements

Diagnosis: breast cancer; gynecological carcinoma

Age: 18 years and older

Line of therapy: Unabhängig von Therapielinie

Key inclusion criteria: under tumor therapy

Allocation

Einarmigen Studie

Treatment

Validated disease-specific questionnairesAnalysis of subjective impairment of the bladder, bowel and sexual function under systemic tumor therapy

Follow-up

12 months

Detailed description

Breast cancer and gynecological cancers, such as uterine cancer, ovarian cancer, or vulvar cancer, often require intensive cancer treatment, which can also have side effects on the pelvic floor. The pelvic floor plays an important role in bladder and bowel control, as well as in sexual function. Impairment of these functions can significantly reduce patients’ quality of life.

The aim of this observational study is to document these impairments using validated questionnaires on pelvic floor function and to identify possible contributing factors. The study will investigate the extent to which systemic (pharmacological) cancer treatments, such as chemotherapy or anti-hormone therapy, lead to changes in pelvic floor function. This is an observational study, which means that no new medications or treatment modalities are being tested. The study focuses on clinically relevant deteriorations in pelvic floor function occurring within 12 months.

Women and men aged 18 and older who have breast cancer or a gynecological tumor and are currently undergoing systemic cancer therapy are eligible to participate.

Facts

  1. Condition: Breast cancer and gynecological cancers (uterine, ovarian, and vulvar cancer)
  2. Cancer characteristics: currently undergoing systemic cancer therapy
  3. What the study investigates: pelvic floor function and quality of life during cancer therapy
  4. Study objective: Assessment of pelvic floor dysfunction, particularly bladder, bowel, and sexual function
  5. How long will the study last: Total duration 3 years; follow-up over 12 months
  6. Study characteristics: Observational study; unblinded; no new medications or treatment modalities are being tested

Trial sites

1 trial site in Germany is listed.

  • St. Josefs-Hospital Wiesbaden GmbH

    Beethovenstraße 20, 65189 Wiesbaden

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT04655066) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.